Literature DB >> 21112196

Kava hepatotoxicity solution: A six-point plan for new kava standardization.

Rolf Teschke1, Jerome Sarris, Vincent Lebot.   

Abstract

Kava-induced liver injury has been demonstrated in a few patients worldwide and appears to be caused by inappropriate quality of the kava raw material. When cases of liver disease in connection with the use of kava emerged, this was an unexpected and challenging event considering the long tradition of safe kava use. In order to prevent kava hepatotoxicity in future, a set of quality specifications as standard is essential for the preparation not only of kava drugs and kava dietary supplements in the Western world but also for traditional kava drinks in the South Pacific Islands. For all these purposes a uniform approach is required, using water based extracts from the peeled rhizomes and roots of a noble cultivar such as Borogu with at least 5 years of age at the time of harvest. Cultivated in Vanuatu for centuries, noble varieties (as defined in the Vanuatu Kava Act of December 2002) are well tolerated traditional cultivars with a good safety record. At present, Vanuatu kava legislation is inadequately enforced to meet quality issues for kava, and further efforts are required in Vanuatu, in addition to similar legislation in other kava producing South Pacific Islands. Future regulatory and commercial strategies should focus not only on the standardization of kava drugs, kava dietary supplements, and traditional kava extracts, but also on thorough surveillance during the manufacturing process to improve kava quality for safe human use. The efficacy of kava extracts to treat patients with anxiety disorders is well supported, but further clinical trials with aqueous kava extracts are necessary. We thereby propose a six-point kava solution plan: (1) use of a noble kava cultivar such as Borogu, at least 5 years old at time of harvest, (2) use of peeled and dried rhizomes and roots, (3) aqueous extraction, (4) dosage recommendation of ≤250mg kavalactones per day (for medicinal use), (5) systematic rigorous future research, and (6) a Pan Pacific quality control system enforced by strict policing. In conclusion, at different levels of responsibility, new mandatory approaches are now required to implement quality specification for international acceptance of kava as a safe and effective anxiolytic herb. 2010. Published by Elsevier GmbH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112196     DOI: 10.1016/j.phymed.2010.10.002

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  9 in total

1.  Pilot in Vivo Structure-Activity Relationship of Dihydromethysticin in Blocking 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced O6-Methylguanine and Lung Tumor in A/J Mice.

Authors:  Manohar Puppala; Sreekanth C Narayanapillai; Pablo Leitzman; Haifeng Sun; Pramod Upadhyaya; M Gerard O'Sullivan; Stephen S Hecht; Chengguo Xing
Journal:  J Med Chem       Date:  2017-09-13       Impact factor: 7.446

Review 2.  Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs.

Authors:  Rolf Teschke; Dominique Larrey; Dieter Melchart; Gaby Danan
Journal:  Medicines (Basel)       Date:  2016-07-19

Review 3.  Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods.

Authors:  Rolf Teschke; Christian Frenzel; Johannes Schulze; Axel Eickhoff
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

4.  Toxicokinetics of kava.

Authors:  Anthony Rowe; Lillian Yuan Zhang; Iqbal Ramzan
Journal:  Adv Pharmacol Sci       Date:  2011-03-21

5.  Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster).

Authors:  Amanda C Martin; Ed Johnston; Chengguo Xing; Adrian D Hegeman
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 6.  Hepatotoxicity Induced by "the 3Ks": Kava, Kratom and Khat.

Authors:  Flaminia Pantano; Roberta Tittarelli; Giulio Mannocchi; Simona Zaami; Serafino Ricci; Raffaele Giorgetti; Daniela Terranova; Francesco P Busardò; Enrico Marinelli
Journal:  Int J Mol Sci       Date:  2016-04-16       Impact factor: 5.923

Review 7.  An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava.

Authors:  Rita B Soares; Ricardo Jorge Dinis-Oliveira; Nuno G Oliveira
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

8.  Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence.

Authors:  J Sarris; S Moylan; D A Camfield; M P Pase; D Mischoulon; M Berk; F N Jacka; I Schweitzer
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-27       Impact factor: 2.629

Review 9.  Kava as a Clinical Nutrient: Promises and Challenges.

Authors:  Tengfei Bian; Pedro Corral; Yuzhi Wang; Jordy Botello; Rick Kingston; Tyler Daniels; Ramzi G Salloum; Edward Johnston; Zhiguang Huo; Junxuan Lu; Andrew C Liu; Chengguo Xing
Journal:  Nutrients       Date:  2020-10-05       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.